Danish pharmaceutical company Genmab announces that global net sales of the cancer drug Darzalex amounted to USD 4,239 million in the third quarter of 2026, according to sales figures from Johnson & Johnson.
Sales in the US amounted to USD 2,528 million, while sales in other markets amounted to USD 1,711 million.
Genmab receives royalties on global net sales of Darzalex, including both intravenous and subcutaneous formulations, under an exclusive global licensing agreement with Johnson & Johnson.
